Journal of Clinical Endocrinology & Metabolism, Vol 74, 623-628, Copyright © 1992 by Endocrine Society

ARTICLES

Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men

AW Meikle, NA Mazer, JF Moellmer, JD Stringham, KG Tolman, SW Sanders and WD Odell
Department of Medicine, University of Utah, Salt Lake City.

None of the current or experimental androgen treatment modalities for male hypogonadism has been reported to produce physiological concentrations or circadian variations in testosterone (T) and its metabolites, dihydrotestosterone (DHT) and estradiol (E2). This investigation describes a novel transdermal dosage form designed to enhance the delivery of native T across nonscrotal skin. The main objective was to determine whether the nightly application of two experimental transdermal patches to different sites on the body (e.g. back, chest, arms, etc.) would result in normal plasma levels of T, DHT, and E2 for men and mimic the normal circadian variation. Six hypogonadal males (aged 24-66 yr) were studied 4 weeks after stopping T ester treatment. After single application of two patches, T levels increased from a pretreatment baseline of 5.8 +/- 0.94 nmol/L (mean +/- SE; 167 +/- 27 ng/dL) to an average peak concentration of 44.1 +/- 4.8 nmol/L (1273 +/- 138 ng/dL) 5.7 +/- 0.6 h after application and reached a 24-h level of 16.9 +/- 2.9 nmol/L (488 +/- 85 ng/dL). DHT and E2 levels exhibited parallel variations within the normal reference ranges. During 4 weeks of daily evening application to various sites on the torso, the mean delivery of T from two patches was 5.2 +/- 0.1 mg/day (approximately 20% of the patch content), and morning T levels were within the normal limits. On day 28 of treatment, the 24-h plasma profiles of T, DHT, and E2 (obtained with two patches on the back) approximately mimicked the normal circadian variations reported in healthy young men. The time-averaged T level was 21.8 +/- 2.9 nmol/L (629 +/- 84 ng/dL), and the plasma concentration ratios of DHT/T (0.07 +/- 0.01) and E2/T (0.005 +/- 0.001) were within the normal range. SHBG concentrations were not significantly altered over the 4 weeks of treatment. The patches were well tolerated, except for one patient who developed a local reaction to an excipient during the third week of treatment. Two of the patients (one with Klinefelter's syndrome) completed several months of continuous therapy. T, DHT, and E2 have remained in the range of normal, and plasma LH levels in the patient with Klinefelter's syndrome became normal. Subjective improvement in symptoms has continued, and tolerability has been good in both patients. These results indicate that the enhanced transdermal delivery of T across nonscrotal skin is a patient-friendly androgen replacement modality and produces physiological concentrations of T and its metabolites, which are unattainable with other treatment modalities.

This article has been cited by other articles:

				A. Mueller, F. Kiesewetter, H. Binder, M. W. Beckmann, and R. Dittrich Long-Term Administration of Testosterone Undecanoate Every 3 Months for Testosterone Supplementation in Female-to-Male Transsexuals J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3470 - 3475. [Abstract] [Full Text] [PDF]

				M. Wald, R. B. Meacham, L. S. Ross, and C. S. Niederberger Testosterone Replacement Therapy for Older Men J Androl, March 1, 2006; 27(2): 126 - 132. [Full Text] [PDF]

				M. Schubert, T. Minnemann, D. Hubler, D. Rouskova, A. Christoph, M. Oettel, M. Ernst, U. Mellinger, W. Krone, and F. Jockenhovel Intramuscular Testosterone Undecanoate: Pharmacokinetic Aspects of a Novel Testosterone Formulation during Long-Term Treatment of Men with Hypogonadism J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5429 - 5434. [Abstract] [Full Text] [PDF]

				C. Wang, R. Swerdloff, M. Kipnes, A. M. Matsumoto, A. S. Dobs, G. Cunningham, L. Katznelson, T. J. Weber, T. C. Friedman, P. Snyder, et al. New Testosterone Buccal System (Striant) Delivers Physiological Testosterone Levels: Pharmacokinetics Study in Hypogonadal Men J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3821 - 3829. [Abstract] [Full Text] [PDF]

				E. Moore, A. Wisniewski, and A. Dobs Endocrine Treatment of Transsexual People: A Review of Treatment Regimens, Outcomes, and Adverse Effects J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3467 - 3473. [Abstract] [Full Text] [PDF]

				R. A. Anderson and D. T. Baird Male Contraception Endocr. Rev., December 1, 2002; 23(6): 735 - 762. [Abstract] [Full Text] [PDF]

				R. A. Anderson, D. Kinniburgh, and D. T. Baird Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3640 - 3649. [Abstract] [Full Text] [PDF]

				W. M. Hair, K. Kitteridge, D. B. O'Connor, and F. C. W. Wu A Novel Male Contraceptive Pill-Patch Combination: Oral Desogestrel and Transdermal Testosterone in the Suppression of Spermatogenesis in Normal Men J. Clin. Endocrinol. Metab., November 1, 2001; 86(11): 5201 - 5209. [Abstract] [Full Text] [PDF]

				A. Vermeulen Androgen Replacement Therapy in the Aging Male--A Critical Evaluation J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2380 - 2390. [Full Text] [PDF]

				R. S. Swerdloff, C. Wang, G. Cunningham, A. Dobs, A. Iranmanesh, A. M. Matsumoto, P. J. Snyder, T. Weber, J. Longstreth, and N. Berman Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4500 - 4510. [Abstract] [Full Text]

				C. Wang, R. S. Swerdloff, A. Iranmanesh, A. Dobs, P. J. Snyder, G. Cunningham, A. M. Matsumoto, T. Weber, and N. Berman the Testosterone Gel Study Group Transdermal Testosterone Gel Improves Sexual Function, Mood, Muscle Strength, and Body Composition Parameters in Hypogonadal Men J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2839 - 2853. [Abstract] [Full Text]

				C. Wang, N. Berman, J. A. Longstreth, B. Chuapoco, L. Hull, B. Steiner, S. Faulkner, R. E. Dudley, and R. S. Swerdloff Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal Men: Application of Gel at One Site Versus Four Sites: A General Clinical Research Center Study J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 964 - 969. [Abstract] [Full Text]

				S. Bhasin and M. Javanbakht Can Androgen Therapy Replete Lean Body Mass and Improve Muscle Function in Wasting Associated With Human Immunodeficiency Virus Infection? JPEN J Parenter Enteral Nutr, November 1, 1999; 23(6_suppl): S195 - S201. [Abstract] [PDF]

				A. S. Dobs, A. W. Meikle, S. Arver, S. W. Sanders, K. E. Caramelli, and N. A. Mazer Pharmacokinetics, Efficacy, and Safety of a Permeation-Enhanced Testosterone Transdermal System in Comparison with Bi-Weekly Injections of Testosterone Enanthate for the Treatment of Hypogonadal Men J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3469 - 3478. [Abstract] [Full Text] [PDF]

				R. A. Anderson, C. W. Martin, A. W. C. Kung, D. Everington, T. C. Pun, K. C. B. Tan, J. Bancroft, K. Sundaram, A. J. Moo-Young, and D. T. Baird 7{alpha}-Methyl-19-Nortestosterone Maintains Sexual Behavior and Mood in Hypogonadal Men J. Clin. Endocrinol. Metab., October 1, 1999; 84(10): 3556 - 3562. [Abstract] [Full Text] [PDF]

				S. J. Winters Current Status of Testosterone Replacement Therapy in Men Arch Fam Med, May 1, 1999; 8(3): 257 - 263. [Abstract] [Full Text] [PDF]

				S. Bhasin, T. W. Storer, N. Asbel-Sethi, A. Kilbourne, R. Hays, I. Sinha-Hikim, R. Shen, S. Arver, and G. Beall Effects of Testosterone Replacement with a Nongenital, Transdermal System, Androderm, in Human Immunodeficiency Virus-Infected Men with Low Testosterone Levels J. Clin. Endocrinol. Metab., September 1, 1998; 83(9): 3155 - 3162. [Abstract] [Full Text]

				A. S. Dobs, D. R. Hoover, M.-C. Chen, and R. Allen Pharmacokinetic Characteristics, Efficacy, and Safety of Buccal Testosterone in Hypogonadal Males: A Pilot Study J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 33 - 39. [Abstract] [Full Text]

				S. Bhasin and W. J. Bremner Emerging Issues in Androgen Replacement Therapy J. Clin. Endocrinol. Metab., January 1, 1997; 82(1): 3 - 8. [Full Text] [PDF]

				C. J. Bagatell and W. J. Bremner Androgens in Men -- Uses and Abuses N. Engl. J. Med., March 14, 1996; 334(11): 707 - 715. [Full Text] [PDF]